Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade

Seong Keun Yoo; Diego Chowell; Cristina Valero; Luc G.T. Morris; Timothy A. Chan

doi:10.1038/s41698-022-00267-7

Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade

Seong Keun Yoo, Diego Chowell, Cristina Valero, Luc G.T. Morris, Timothy A. Chan

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

The effects of cytokine and protein stabilizing carriers, such as serum albumin, on tumor response to immune checkpoint blockade (ICB) is not well understood. By examining 1714 patients across 16 cancer types, we found that high pretreatment serum albumin level predicts favorable tumor radiographic response following ICB treatment in a dose-dependent fashion. Serum albumin is a candidate biomarker that can be combined with tumor mutational burden (TMB) for additional predictive capacity, and the tumor response rate to ICB was ~49% in the albumin-high/TMB-high group.

Original language	English
Article number	23
Journal	npj Precision Oncology
Volume	6
Issue number	1
DOIs	https://doi.org/10.1038/s41698-022-00267-7
State	Published - Dec 2022

Access to Document

10.1038/s41698-022-00267-7

Cite this

@article{8aee2d399a8c459982cb99e370a6781c,

title = "Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade",

abstract = "The effects of cytokine and protein stabilizing carriers, such as serum albumin, on tumor response to immune checkpoint blockade (ICB) is not well understood. By examining 1714 patients across 16 cancer types, we found that high pretreatment serum albumin level predicts favorable tumor radiographic response following ICB treatment in a dose-dependent fashion. Serum albumin is a candidate biomarker that can be combined with tumor mutational burden (TMB) for additional predictive capacity, and the tumor response rate to ICB was ~49% in the albumin-high/TMB-high group.",

author = "Yoo, {Seong Keun} and Diego Chowell and Cristina Valero and Morris, {Luc G.T.} and Chan, {Timothy A.}",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = dec,

doi = "10.1038/s41698-022-00267-7",

language = "English",

volume = "6",

journal = "npj Precision Oncology",

issn = "2397-768X",

publisher = "Springer Nature",

number = "1",

}

TY - JOUR

T1 - Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade

AU - Yoo, Seong Keun

AU - Chowell, Diego

AU - Valero, Cristina

AU - Morris, Luc G.T.

AU - Chan, Timothy A.

PY - 2022/12

Y1 - 2022/12

N2 - The effects of cytokine and protein stabilizing carriers, such as serum albumin, on tumor response to immune checkpoint blockade (ICB) is not well understood. By examining 1714 patients across 16 cancer types, we found that high pretreatment serum albumin level predicts favorable tumor radiographic response following ICB treatment in a dose-dependent fashion. Serum albumin is a candidate biomarker that can be combined with tumor mutational burden (TMB) for additional predictive capacity, and the tumor response rate to ICB was ~49% in the albumin-high/TMB-high group.

AB - The effects of cytokine and protein stabilizing carriers, such as serum albumin, on tumor response to immune checkpoint blockade (ICB) is not well understood. By examining 1714 patients across 16 cancer types, we found that high pretreatment serum albumin level predicts favorable tumor radiographic response following ICB treatment in a dose-dependent fashion. Serum albumin is a candidate biomarker that can be combined with tumor mutational burden (TMB) for additional predictive capacity, and the tumor response rate to ICB was ~49% in the albumin-high/TMB-high group.

UR - http://www.scopus.com/inward/record.url?scp=85128044516&partnerID=8YFLogxK

U2 - 10.1038/s41698-022-00267-7

DO - 10.1038/s41698-022-00267-7

M3 - Article

AN - SCOPUS:85128044516

SN - 2397-768X

VL - 6

JO - npj Precision Oncology

JF - npj Precision Oncology

IS - 1

M1 - 23

ER -

Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade

Abstract

Access to Document

Fingerprint

Cite this